AN 4005
Alternative Names: AN-4005Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Adlai Nortye
- Class Antineoplastics; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in USA (PO)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (PO)